top of page

Theranostics

Theranostics combines PSMA-PET/CT imaging with a targeting compound (ligand) with a therapeutic radioisotope (radioactive particle) injected into the blood to target the cancer cells. Researchers provide frequent updates.

24-09 Dr. Elie Dolgin "Radiopharmaceuticals"
57:21

24-09 Dr. Elie Dolgin "Radiopharmaceuticals"

24-08 Jeremie Calais, MD PhD "PSMA Theranostics"
01:00:05

24-08 Jeremie Calais, MD PhD "PSMA Theranostics"

23-06 Gary Ulaner, MD, PhD "PSMA-targeted Imaging for Prostate Cancer"
42:21

23-06 Gary Ulaner, MD, PhD "PSMA-targeted Imaging for Prostate Cancer"

22-01. Drs. Auerbach & Calais "Theranostics: Imaging and Treatment of Prostate Cancer" 2022-01-27
01:23:42

22-01. Drs. Auerbach & Calais "Theranostics: Imaging and Treatment of Prostate Cancer" 2022-01-27

20-09. M. Auerbach, MD & J. Calais, MD "PET/CT imaging and radiation therapy for PC" 9-24-20
01:33:29

20-09. M. Auerbach, MD & J. Calais, MD "PET/CT imaging and radiation therapy for PC" 9-24-20

21-01. Dr Nat Lenzo "Radioligand Guided Imaging and Therapy in Prostate Cancer" Jan 28, 2021
01:13:26

21-01. Dr Nat Lenzo "Radioligand Guided Imaging and Therapy in Prostate Cancer" Jan 28, 2021

bottom of page